Sergio Fazio

Professor

  • 14601 Citations
  • 62 h-Index
1979 …2021
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Sergio Fazio is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles
Apolipoproteins E Medicine & Life Sciences
Atherosclerosis Medicine & Life Sciences
Macrophages Medicine & Life Sciences
Cholesterol Medicine & Life Sciences
LDL Receptors Medicine & Life Sciences
Lipoproteins Medicine & Life Sciences
Hydroxymethylglutaryl-CoA Reductase Inhibitors Medicine & Life Sciences
Lipids Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 1979 2021

Lipoproteins
LDL Receptors
Furin
Proprotein Convertase 9
LDL Cholesterol

RESEARCH AND DEVELOPMENT PROGRAM

Fazio, S., Cherrington, A., Hanley, G. A., Granner, D., Vaughan, D. E., Salleng, K., McGuinness, O., Wasserman, D. & Vaughan, D. E.

National Institutes of Health

3/1/016/30/21

Project: Research project

research and development
Pathology
director
technical innovation
Research
HDL Lipoproteins
Cholesterol
Research Personnel
Lipoproteins
Macrophages
Lipoprotein Receptors
LDL Receptors
Atherosclerosis
Cholesterol
Proprotein Convertase 9
Atherosclerosis
Macrophages
Cholesterol
Foam Cells
Blood Vessels

Research Output 1982 2019

7 Citations (Scopus)

Application of PCSK9 Inhibitors in Practice

Kaufman, T., Warden, B. A., Minnier, J., Miles, J. R., Duell, P., Purnell, J., Wojcik, C., Fazio, S. & Shapiro, M., Jan 4 2019, In : Circulation Research. 124, 1, p. 32-37 6 p.

Research output: Contribution to journalArticle

Subtilisin
Proteins
Insurance
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1 Citation (Scopus)

Brief commentary: Marijuana and cardiovascular disease—what should we tell patients?

Kaufman, T., Fazio, S. & Shapiro, M., Jan 15 2019, In : Annals of Internal Medicine. 170, 2, p. 119-120 2 p.

Research output: Contribution to journalComment/debate

Cannabis
Cardiovascular Diseases
Coronary Angiography
Echocardiography
Coronary Artery Disease
Dilatation
Angiography
1 Citation (Scopus)
Lipoprotein(a)
Niacin
Group Psychotherapy
Therapeutics
Proprotein Convertase 9
25 Citations (Scopus)

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

O'Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K. A., Lira Pineda, A., Wasserman, S. M., Češka, R., Ezhov, M. V., Jukema, J. W., Jensen, H. K., Tokgözoğlu, S. L., Mach, F., Huber, K., Sever, P. S., Keech, A. C., Pedersen, T. R. & Sabatine, M. S., Mar 19 2019, In : Circulation. 139, 12, p. 1483-1492 10 p.

Research output: Contribution to journalArticle

Proprotein Convertases
Subtilisin
Lipoprotein(a)
LDL Cholesterol
Numbers Needed To Treat